These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1566 related articles for article (PubMed ID: 18525320)

  • 1. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric GISTs. Personal experience.
    Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
    Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
    J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
    Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
    Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
    Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
    Eisenberg BL; Judson I
    Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
    Catani M; De Milito R; Simi M
    Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
    Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
    Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
    Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
    Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
    Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
    Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
    Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
    Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.